TNFRSF8 and lymphoma: Two recent clinical trials of CD30‐directed Chimeric Antigen Receptor T (CAR‐T) cells in relapsed/refractory (r/r) CD30+ lymphomas have shown preliminary efficacy in patients with heavily treated r/r disease.55, 56, 57, 58